Invivyd (IVVD) Long-Term Investments (2024 - 2026)
Invivyd's (IVVD) quarterly Long-Term Investments came in at $25.3 million in Q2 2026, little changed on a YoY basis from $25.4 million in Q2 2025, and down 0.6% quarter-over-quarter from $25.5 million in Q4 2025.
Analysis
Invivyd (IVVD) Long-Term Investments (2024 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Long-Term Investments for 3 consecutive years, with $25.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Long-Term Investments changed 0.37% year-over-year to $25.3 million; the trailing twelve-month figure through Jun 2026 stood at $25.3 million (changed 0.37% YoY), and the FY2025 full-year result was $25.5 million, down 1.57% from the prior year.
- Long-Term Investments slipped to $25.3 million in Q2 2026 per IVVD's latest filing, from $25.5 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $25.9 million in Q4 2024 and bottomed at $25.3 million in Q2 2026.
- Historically, Long-Term Investments has averaged $25.5 million across 3 years, with a median of $25.4 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Long-Term Investments fell 1.57% in 2025, then dropped 0.37% in 2026.
- Over 3 years, Long-Term Investments stood at $25.9 million in 2024, then dropped by 1.57% to $25.5 million in 2025, then fell by 0.6% to $25.3 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $25.3 million, $25.5 million, and $25.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 5.79 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 9.83 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -4.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 1.77 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 25.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.35 Mn |
| Dec 31, 2025 | 25.50 Mn |
| Sep 30, 2025 | 25.40 Mn |
| Jun 30, 2025 | 25.44 Mn |
| Mar 31, 2025 | 25.42 Mn |
| Dec 31, 2024 | 25.91 Mn |